D
David C. Montefiori
Researcher at Duke University
Publications - 995
Citations - 79717
David C. Montefiori is an academic researcher from Duke University. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 129, co-authored 920 publications receiving 70049 citations. Previous affiliations of David C. Montefiori include Emory University & University of California, Davis.
Papers
More filters
Journal ArticleDOI
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge
Barbara K. Felber,Zhongyan Lu,Xintao Hu,Antonio Valentin,Margherita Rosati,Christopher A.L. Remmel,Joshua A. Weiner,Margaret C. Carpenter,Katelyn Faircloth,Sherry Stanfield-Oakley,Wilton B. Williams,Xiaoying Shen,Georgia D. Tomaras,Celia C. LaBranche,David C. Montefiori,Hung V. Trinh,Hung V. Trinh,Mangala Rao,Munir Alam,Nathan Vandergrift,Kevin O. Saunders,Yunfei Wang,Wes Rountree,Jishnu Das,Galit Alter,Steven G. Reed,Pyone P. Aye,Faith Schiro,Bapi Pahar,Jason Dufour,Ronald S. Veazey,Preston A. Marx,David Venzon,George M. Shaw,Guido Ferrari,Margaret E. Ackerman,Barton F. Haynes,George N. Pavlakis +37 more
TL;DR: Interestingly, only macaques in the co-administration vaccine group are protected against SHIV CH505 acquisition after repeated low-dose intravaginal challenge and show 67% risk reduction per exposure.
Journal ArticleDOI
Targeting HIV-1 envelope glycoprotein trimers to B cells using APRIL improves antibody responses
M Melchers,I Bontjer,T Tong,Nancy P. Y. Chung,Per Johan Klasse,Dirk Eggink,M Gentile,Andrea Cerutti,David C. Montefiori,William C. Olson,Ben Berkhout,James M. Binley,John P. Moore,Rogier W. Sanders +13 more
TL;DR: Targeting and activating B cells with a trimeric HIV-1 Env-APRIL fusion protein may improve the induction of humoral immunity against HIV- 1 and may also be useful for other vaccines.
Journal ArticleDOI
Control of a Mucosal Challenge and Prevention of AIDS in Rhesus Macaques by a Multiprotein DNA/MVA Vaccine
Rama Rao Amara,Francois Villinger,John D. Altman,Shari L. Lydy,Shawn P. O'Neil,Silvija J. Staprans,David C. Montefiori,Yan Xu,James G. Herndon,Linda S. Wyatt,Maria Angelito Candido,Natalia Kozyr,Patricia L. Earl,James M. Smith,Hak-Ling Ma,Bennett D. Grimm,Michael L. Hulsey,Harold M. McClure,Janet M. McNicholl,Bernard Moss,Harriet L. Robinson +20 more
Journal ArticleDOI
In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.
Megan C. Wise,Ziyang Xu,Ziyang Xu,Edgar Tello-Ruiz,Charles Beck,Aspen Trautz,Ami Patel,Sarah T. C. Elliott,Neethu Chokkalingam,Sophie Kim,Melissa Kerkau,Karuppiah Muthumani,Jingjing Jiang,Paul Fisher,Stephany J. Ramos,Trevor R.F. Smith,Janess M. Mendoza,Kate E. Broderick,David C. Montefiori,Guido Ferrari,Daniel W. Kulp,Laurent Humeau,David B. Weiner +22 more
TL;DR: An approach utilizing synthetic DNA-encoded monoclonal antibodies (dMAbs) for direct in vivo production of prespecified neutralizing activity is described and the dMAb approach provides an important local delivery platform for the in vivo generation of HIV-1 bNAbs and for other infectious disease antibodies.
Journal ArticleDOI
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.
Saintedym Wills,Kwan Ki Hwang,Pinghuang Liu,S. Moses Dennison,Matthew Zirui Tay,Xiaoying Shen,Justin Pollara,Judith T. Lucas,Robert Parks,Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayapan,Jaranit Kaewkungwal,Rasmi Thomas,Rasmi Thomas,Jerome H. Kim,Nelson L. Michael,Merlin L. Robb,Merlin L. Robb,Michael D. McRaven,David C. Montefiori,Thomas J. Hope,Hua-Xin Liao,M. Anthony Moody,Guido Ferrari,Barton F. Haynes,S. Munir Alam,Mattia Bonsignori,Georgia D. Tomaras +28 more
TL;DR: Characterization of the functional properties of HIV-1 Env-specific IgA monoclonal antibodies from human vaccine clinical trials are critical toward understanding the capacity of the host immune response to block HIV-2 acquisition and the complex and diverse interactions of vaccine-elicited IgA with pathogens that depend on IgA fine specificity and form in the systemic circulation and mucosal compartments.